PE20231203A1 - Anticuerpos de cadena pesada que se unen al receptor de folato alfa - Google Patents
Anticuerpos de cadena pesada que se unen al receptor de folato alfaInfo
- Publication number
- PE20231203A1 PE20231203A1 PE2023001680A PE2023001680A PE20231203A1 PE 20231203 A1 PE20231203 A1 PE 20231203A1 PE 2023001680 A PE2023001680 A PE 2023001680A PE 2023001680 A PE2023001680 A PE 2023001680A PE 20231203 A1 PE20231203 A1 PE 20231203A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- heavy chain
- receptor alpha
- folate receptor
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115436P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/059701 WO2022109010A1 (en) | 2020-11-18 | 2021-11-17 | Heavy chain antibodies binding to folate receptor alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231203A1 true PE20231203A1 (es) | 2023-08-17 |
Family
ID=79024440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001680A PE20231203A1 (es) | 2020-11-18 | 2021-11-17 | Anticuerpos de cadena pesada que se unen al receptor de folato alfa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240002498A1 (https=) |
| EP (1) | EP4247498A1 (https=) |
| JP (1) | JP2023549851A (https=) |
| KR (1) | KR20230110303A (https=) |
| CN (1) | CN116615253A (https=) |
| AR (1) | AR124084A1 (https=) |
| AU (1) | AU2021383743A1 (https=) |
| CA (1) | CA3199785A1 (https=) |
| CL (2) | CL2023001432A1 (https=) |
| CO (1) | CO2023006790A2 (https=) |
| CR (1) | CR20230259A (https=) |
| IL (1) | IL302670A (https=) |
| JO (1) | JOP20230109A1 (https=) |
| MX (1) | MX2023005693A (https=) |
| PE (1) | PE20231203A1 (https=) |
| TW (1) | TW202233684A (https=) |
| UY (1) | UY39522A (https=) |
| WO (1) | WO2022109010A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2025252094A1 (zh) * | 2024-06-05 | 2025-12-11 | 长春金赛药业有限责任公司 | 靶向叶酸受体α(FRα)的抗体、双特异性抗体和偶联物，及其制备和用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| DK3221355T3 (da) * | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| CN115925952A (zh) * | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| JP7776987B2 (ja) * | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
-
2021
- 2021-11-11 TW TW110142033A patent/TW202233684A/zh unknown
- 2021-11-17 EP EP21824720.3A patent/EP4247498A1/en active Pending
- 2021-11-17 CA CA3199785A patent/CA3199785A1/en active Pending
- 2021-11-17 MX MX2023005693A patent/MX2023005693A/es unknown
- 2021-11-17 KR KR1020237020120A patent/KR20230110303A/ko active Pending
- 2021-11-17 PE PE2023001680A patent/PE20231203A1/es unknown
- 2021-11-17 US US18/253,197 patent/US20240002498A1/en active Pending
- 2021-11-17 CR CR20230259A patent/CR20230259A/es unknown
- 2021-11-17 CN CN202180077625.6A patent/CN116615253A/zh active Pending
- 2021-11-17 AR ARP210103178A patent/AR124084A1/es unknown
- 2021-11-17 JP JP2023528641A patent/JP2023549851A/ja active Pending
- 2021-11-17 IL IL302670A patent/IL302670A/en unknown
- 2021-11-17 AU AU2021383743A patent/AU2021383743A1/en active Pending
- 2021-11-17 WO PCT/US2021/059701 patent/WO2022109010A1/en not_active Ceased
- 2021-11-18 UY UY0001039522A patent/UY39522A/es unknown
-
2023
- 2023-05-18 JO JOJO/P/2023/0109A patent/JOP20230109A1/ar unknown
- 2023-05-18 CL CL2023001432A patent/CL2023001432A1/es unknown
- 2023-05-25 CO CONC2023/0006790A patent/CO2023006790A2/es unknown
-
2025
- 2025-10-14 CL CL2025003126A patent/CL2025003126A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY39522A (es) | 2022-06-30 |
| IL302670A (en) | 2023-07-01 |
| JP2023549851A (ja) | 2023-11-29 |
| AU2021383743A1 (en) | 2023-06-08 |
| AR124084A1 (es) | 2023-02-08 |
| JOP20230109A1 (ar) | 2023-05-18 |
| WO2022109010A1 (en) | 2022-05-27 |
| CR20230259A (es) | 2023-07-13 |
| CN116615253A (zh) | 2023-08-18 |
| CL2023001432A1 (es) | 2024-01-05 |
| AU2021383743A9 (en) | 2024-09-26 |
| US20240002498A1 (en) | 2024-01-04 |
| MX2023005693A (es) | 2023-05-29 |
| CO2023006790A2 (es) | 2023-06-09 |
| KR20230110303A (ko) | 2023-07-21 |
| CA3199785A1 (en) | 2022-05-27 |
| CL2025003126A1 (es) | 2026-01-23 |
| EP4247498A1 (en) | 2023-09-27 |
| TW202233684A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231203A1 (es) | Anticuerpos de cadena pesada que se unen al receptor de folato alfa | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| GEP20197034B (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20180795A1 (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20201149A1 (es) | Anticuerpos de union a hla-a2/wt1 | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
| PE20200888A1 (es) | Anticuerpos biespecificos que se unen a los epitopos del virus del zika |